Gene Gun Technology, Opioids, and Corneal Diseases
基因枪技术、阿片类药物和角膜疾病
基本信息
- 批准号:6417142
- 负责人:
- 金额:$ 13.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-08-01 至 2004-07-31
- 项目状态:已结题
- 来源:
- 关键词:biotechnology cornea disorder corneal epithelium endogenous opioid evaluation /testing gene delivery system gene therapy genetic transcription histochemistry /cytochemistry homeostasis human tissue laboratory rat nonhuman therapy evaluation opioid receptor organ culture technology /technique development western blottings wound healing
项目摘要
DESCRIPTION: (Applicant's Abstract) The corneal epithelium modulates fluid
transport for normal stromal hydration and corneal transparency, and serves as
an anatomical and physiological barrier against ocular infection. This
epithelium is in a constant state of renewal, and injury to this epithelium
requires prompt resurfacing in order to re-establish visual function. Tools to
achieve research and clinical applications to corneal diseases at the molecular
level offer exciting avenues for advancement, but are stymied by the need for
manipulating gene activity. Progress has been made in gene therapy through the
development of a particle-mediated gene transfer delivery system (gene gun), a
technique shown to be a rapid, highly efficient, and nontoxic method for
transfection of genes both in vivo and in vitro. In this grant we propose to
establish the gene gun as a valuable research tool in corneal epithelial
biology, obtain preliminary information for the efficacy of the gene gun as a
device for clinical treatment, and document the importance of the interaction
of a native inhibitory peptide, opioid growth factor (OGF) with its receptor
(OGFr) at the molecular level as a system regulating the homeostasis and
healing of the ocular surface epithelium in humans and animals. The specific
aims include: 1. Determine the importance of OGF-OGFr interfacing on
maintenance of rat corneal epithelium by examining the consequences of
molecular perturbation of OGF receptor gene and protein activity. 2. Define the
role of an endogenous opioid system related to wound healing of the rat corneal
epithelium following genetic alteration of the OGF receptor gene and protein
expression in rat. 3. Ascertain the significance of OGF and OGFr function
during wound healing of the human corneal epithelium using organ culture of
tissues genetically modified to yield an excess or deficit of OGF receptor.
Information derived from these studies will contribute to a breakthrough
understanding of gene delivery systems to the corneal surface. Moreover, these
investigations will simultaneously acquire invaluable knowledge about the
molecular basis by which an endogenous opioid system relates to corneal
epithelial homeostasis, and the restoration of corneal integrity following
injury. Ultimately, such data can be employed to design molecular strategies to
remedy visual dysfunction.
描述:(申请人摘要)角膜上皮调节液体
正常基质水合作用和角膜透明度的运输,并充当
对抗眼部感染的解剖学和生理学屏障。这
上皮处于不断更新的状态,并且上皮受到损伤
需要立即重新表面以重新建立视觉功能。工具
在分子水平上实现角膜疾病的研究和临床应用
级别提供了令人兴奋的晋升途径,但由于需要
操纵基因活性。基因治疗已取得进展
开发粒子介导的基因转移传递系统(基因枪)
该技术被证明是一种快速、高效、无毒的方法
体内和体外基因转染。在这笔赠款中,我们建议
建立基因枪作为角膜上皮有价值的研究工具
生物学,获得基因枪作为一种药物的功效的初步信息
临床治疗设备,并记录相互作用的重要性
天然抑制肽阿片生长因子 (OGF) 及其受体
(OGFr)在分子水平上作为调节体内平衡的系统
人类和动物眼表上皮的愈合。具体的
目标包括: 1. 确定 OGF-OGFr 连接的重要性
通过检查后果来维持大鼠角膜上皮
OGF 受体基因和蛋白质活性的分子扰动。 2. 定义
内源性阿片类系统在大鼠角膜伤口愈合中的作用
OGF 受体基因和蛋白质遗传改变后的上皮细胞
在大鼠中的表达。 3. 确定OGF和OGFr功能的意义
在人角膜上皮伤口愈合过程中使用器官培养
组织经过基因改造,产生过量或缺乏的 OGF 受体。
从这些研究中获得的信息将有助于取得突破
了解角膜表面的基因传递系统。而且,这些
调查将同时获得有关该问题的宝贵知识
内源性阿片类药物系统与角膜相关的分子基础
上皮稳态以及术后角膜完整性的恢复
受伤。最终,这些数据可以用来设计分子策略
治疗视力障碍。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
IAN S ZAGON其他文献
IAN S ZAGON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('IAN S ZAGON', 18)}}的其他基金
OGF-OGFr Axis Modulation to Prevent Diabetic Ocular Surface Complications.
OGF-OGFr 轴调节可预防糖尿病眼表并发症。
- 批准号:
10203997 - 财政年份:2018
- 资助金额:
$ 13.28万 - 项目类别:
OGF-OGFr Axis Modulation to Prevent Diabetic Ocular Surface Complications.
OGF-OGFr 轴调节可预防糖尿病眼表并发症。
- 批准号:
9789327 - 财政年份:2018
- 资助金额:
$ 13.28万 - 项目类别:
Naltrexone as a Novel Treatment for Diabetic Keratopathy
纳曲酮作为糖尿病角膜病的新型治疗方法
- 批准号:
7287707 - 财政年份:2004
- 资助金额:
$ 13.28万 - 项目类别:
Naltrexone as a Novel Treatment for Diabetic Keratopathy
纳曲酮作为糖尿病角膜病的新型治疗方法
- 批准号:
6954645 - 财政年份:2004
- 资助金额:
$ 13.28万 - 项目类别:
Naltrexone as a Novel Treatment for Diabetic Keratopathy
纳曲酮作为糖尿病角膜病的新型治疗方法
- 批准号:
6857373 - 财政年份:2004
- 资助金额:
$ 13.28万 - 项目类别:
Naltrexone as a Novel Treatment for Diabetic Keratopathy
纳曲酮作为糖尿病角膜病的新型治疗方法
- 批准号:
7122771 - 财政年份:2004
- 资助金额:
$ 13.28万 - 项目类别:
Naltrexone as a Novel Treatment for Diabetic Keratopathy
纳曲酮作为糖尿病角膜病的新型治疗方法
- 批准号:
8011240 - 财政年份:2004
- 资助金额:
$ 13.28万 - 项目类别:
Gene Gun Technology, Opioids, and Corneal Diseases
基因枪技术、阿片类药物和角膜疾病
- 批准号:
6641233 - 财政年份:2001
- 资助金额:
$ 13.28万 - 项目类别:
Gene Gun Technology, Opioids, and Corneal Diseases
基因枪技术、阿片类药物和角膜疾病
- 批准号:
6525355 - 财政年份:2001
- 资助金额:
$ 13.28万 - 项目类别:
REGULATION OF CORNEAL WOUND HEALING IN TYPE I DIABETES
I 型糖尿病角膜伤口愈合的调节
- 批准号:
6207738 - 财政年份:1999
- 资助金额:
$ 13.28万 - 项目类别: